GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (LTS:0JXI) » Definitions » Earnings per Share (Diluted)

Madrigal Pharmaceuticals (LTS:0JXI) Earnings per Share (Diluted) : $-18.05 (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Madrigal Pharmaceuticals Earnings per Share (Diluted)?

Madrigal Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was $-3.32. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-18.05.

Madrigal Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2025 was $-3.32. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was $-18.05.

Madrigal Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2025 was $-3.32. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was $-18.05.

During the past 3 years, the average EPS without NRIGrowth Rate was -14.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -27.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was -4.20% per year.

During the past 13 years, Madrigal Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 61.90% per year. The lowest was -165.80% per year. And the median was -10.90% per year.


Madrigal Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Madrigal Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Earnings per Share (Diluted) Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.09 -14.63 -17.23 -19.99 -21.90

Madrigal Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.38 -7.10 -4.92 -2.71 -3.32

Competitive Comparison of Madrigal Pharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, Madrigal Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's PE Ratio falls into.


;
;

Madrigal Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Madrigal Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-465.892-0)/21.273
=-21.90

Madrigal Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2025 is calculated as

Diluted Earnings Per Share (Q: Mar. 2025 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-73.238-0)/22.091
=-3.32

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Madrigal Pharmaceuticals  (LTS:0JXI) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Madrigal Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Madrigal Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals Headlines

No Headlines